JPWO2021116872A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021116872A5 JPWO2021116872A5 JP2022534860A JP2022534860A JPWO2021116872A5 JP WO2021116872 A5 JPWO2021116872 A5 JP WO2021116872A5 JP 2022534860 A JP2022534860 A JP 2022534860A JP 2022534860 A JP2022534860 A JP 2022534860A JP WO2021116872 A5 JPWO2021116872 A5 JP WO2021116872A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- poloxamer
- composition according
- polyethylene glycol
- cabotegravir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 11
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 claims 9
- 229950005928 cabotegravir Drugs 0.000 claims 9
- 229920001983 poloxamer Polymers 0.000 claims 8
- 229960000502 poloxamer Drugs 0.000 claims 8
- 239000002202 Polyethylene glycol Substances 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 4
- 229920002517 Poloxamer 338 Polymers 0.000 claims 3
- 229920001992 poloxamer 407 Polymers 0.000 claims 3
- 229940044476 poloxamer 407 Drugs 0.000 claims 3
- 229940050929 polyethylene glycol 3350 Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920002511 Poloxamer 237 Polymers 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945412P | 2019-12-09 | 2019-12-09 | |
| US62/945,412 | 2019-12-09 | ||
| US202062982305P | 2020-02-27 | 2020-02-27 | |
| US62/982,305 | 2020-02-27 | ||
| PCT/IB2020/061582 WO2021116872A1 (en) | 2019-12-09 | 2020-12-07 | Pharmaceutical compositions comprising cabotegravir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505543A JP2023505543A (ja) | 2023-02-09 |
| JPWO2021116872A5 true JPWO2021116872A5 (es) | 2023-12-15 |
Family
ID=73834567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534860A Pending JP2023505543A (ja) | 2019-12-09 | 2020-12-07 | カボテグラビルを含んでなる医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230045509A1 (es) |
| EP (1) | EP4072520A1 (es) |
| JP (1) | JP2023505543A (es) |
| KR (1) | KR20220112771A (es) |
| CN (1) | CN114786648A (es) |
| AU (1) | AU2020402659A1 (es) |
| BR (1) | BR112022010574A2 (es) |
| CA (1) | CA3164528A1 (es) |
| IL (1) | IL293566A (es) |
| MX (1) | MX2022006940A (es) |
| TW (1) | TW202135815A (es) |
| UY (1) | UY38982A (es) |
| WO (1) | WO2021116872A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230321089A1 (en) | 2020-09-01 | 2023-10-12 | Viiv Healthcare Company | Combination of cabotegravir and levonorgestrel |
| EP4255472A2 (en) * | 2020-12-07 | 2023-10-11 | VIIV Healthcare Company | Combination therapy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550155B2 (en) * | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| PT3284520T (pt) | 2005-04-28 | 2019-09-10 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| US20170165271A1 (en) * | 2014-02-24 | 2017-06-15 | The Board Of Regents Of The University Of Nebraska | Compositions and Methods for the Delivery of Therapeutics |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| SG11201608041QA (en) * | 2014-04-11 | 2016-10-28 | Viiv Healthcare Uk No 4 Ltd | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
| AU2015323321A1 (en) * | 2014-09-26 | 2017-04-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| ES2902136T3 (es) * | 2016-02-12 | 2022-03-25 | Cipla Ltd | Composiciones farmacéuticas que comprenden un fármaco antirretrovírico y un potenciador farmacocinético |
| JP7160466B2 (ja) * | 2016-06-23 | 2022-10-25 | ヴィーブ ヘルスケア カンパニー | 治療薬の送達のための組成物及び方法 |
| US20190328900A1 (en) * | 2016-07-01 | 2019-10-31 | Glaxosmithkline Intellectual Property Development Limited | Antibody-drug conjugates and therapeutic methods using the same |
| UY37710A (es) * | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| US20200407393A1 (en) * | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
| US11505543B2 (en) * | 2018-04-11 | 2022-11-22 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| PT3784349T (pt) * | 2018-04-24 | 2024-01-22 | Viiv Healthcare Uk No 5 Ltd | Compostos com atividade inibidora de maturação do hiv |
| CN112423750A (zh) * | 2018-07-16 | 2021-02-26 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| WO2020084492A1 (en) | 2018-10-24 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN113382737A (zh) * | 2018-11-29 | 2021-09-10 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| CN113811360A (zh) | 2019-03-06 | 2021-12-17 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 用于hiv治疗的化合物 |
| EP3962603A1 (en) * | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| RS65304B1 (sr) * | 2019-06-19 | 2024-04-30 | Viiv Healthcare Uk No 5 Ltd | Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije humanog imunodeficijentnog virusa |
| BR112022004417A2 (pt) * | 2019-09-11 | 2022-06-21 | Scripps Research Inst | Pró-fármacos antivirais e composições farmacêuticas dos mesmos |
-
2020
- 2020-12-07 UY UY0001038982A patent/UY38982A/es unknown
- 2020-12-07 JP JP2022534860A patent/JP2023505543A/ja active Pending
- 2020-12-07 AU AU2020402659A patent/AU2020402659A1/en active Pending
- 2020-12-07 US US17/756,971 patent/US20230045509A1/en active Pending
- 2020-12-07 IL IL293566A patent/IL293566A/en unknown
- 2020-12-07 EP EP20824345.1A patent/EP4072520A1/en active Pending
- 2020-12-07 BR BR112022010574A patent/BR112022010574A2/pt not_active Application Discontinuation
- 2020-12-07 KR KR1020227018750A patent/KR20220112771A/ko unknown
- 2020-12-07 WO PCT/IB2020/061582 patent/WO2021116872A1/en unknown
- 2020-12-07 CA CA3164528A patent/CA3164528A1/en active Pending
- 2020-12-07 TW TW109143111A patent/TW202135815A/zh unknown
- 2020-12-07 CN CN202080085115.9A patent/CN114786648A/zh active Pending
- 2020-12-07 MX MX2022006940A patent/MX2022006940A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021098728A5 (es) | ||
| JP2021073187A (ja) | 即効型インスリン組成物 | |
| EP2292235A3 (de) | Methotrexat-Lösungen | |
| JP2022191257A5 (es) | ||
| JP2016147856A5 (es) | ||
| ES2830447T3 (es) | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación | |
| JP2017530953A5 (es) | ||
| JP2005343897A5 (es) | ||
| Green et al. | Nicotine enemas for active ulcerative colitis—a pilot study | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| TWI812580B (zh) | 檸檬酸鐵用於治療缺鐵性貧血之用途 | |
| JP2010513229A (ja) | 軽減された肝毒性を含む最小限に抑制された副作用を有するアセトアミノフェン組成物 | |
| Evans et al. | Short‐duration therapy with terbinafine 1% cream in dermatophyte skin infections | |
| JP2019533715A5 (es) | ||
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2016512247A5 (es) | ||
| JPWO2021116872A5 (es) | ||
| RU2014113941A (ru) | Суспензия для перорального введения | |
| JP2019507174A5 (es) | ||
| JP2003511396A5 (es) | ||
| JP2005529152A5 (es) | ||
| JP2015524808A5 (es) | ||
| JP2019535830A5 (es) | ||
| RU2018130097A (ru) | Лечение экземы кистей | |
| RU2018118603A (ru) | Фармацевтические композиции диметилфумарата |